InvestorsHub Logo
Followers 46
Posts 1362
Boards Moderated 0
Alias Born 08/09/2015

Re: neiu post# 165923

Tuesday, 09/18/2018 7:58:13 PM

Tuesday, September 18, 2018 7:58:13 PM

Post# of 460674
Neiu: Thank you. Note that this patent pertains to:

”This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73), ANAVEX1-41 and/or Anavex19-144 in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.”

What about the additional reference to MS?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News